To read the full story, subscribe or sign in.

Dualitas launches with $65M to advance bispecifics for I&I

Sep. 16, 2025

Dualitas Therapeutics Inc. exited stealth mode with a $65 million series A investment that was co-led by Versant Ventures and Qiming Venture Partners USA.

BioWorld Financings Immune Inflammatory Bispecific antibody Series A

Today's news in brief

BioWorld

BioWorld briefs for Jan 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 5, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...